Currently, works are being carried out on the implementation of the elements of "Industry 4.0" in Kazakhstan. The introduction of digital technologies in production will be one of the success factors of Kazakhstani enterprises and will allow optimization of production processes.

The SANTO company, being a part of the international pharmaceutical group "Polpharma" (Poland), is a major investment in the field of modernizing the existing pharmaceutical production of JSC "Khimfarm" in South Kazakhstan region in accordance with cGMP (EnglishGoodManufacturingPractice;Good manufacturing practice) implements the project.

In the period of 2018-2022, within the framework of the fourth stage of the modernization of the large Kazakh factory for the production of medicines of JSC "Khimfarm", a new laboratory will be built, infrastructure will be modernized, logistics facilities will be modernized, research and development equipment will be modernized. And, in March 2018, a new section of non-sterilized solutions will be launched.

It is planned to spend significant financial resources on automation and digitization of primary and secondary production processes: innovative IT solution in personnel management - "Cloud HR"; "smart" system of management of warehouses at production sites, system of automation of planning and accounting of routine work on maintenance and repair; planning of human and material resources; automation and management of quality assurance in production and others.

Polish investors will spend about 37 million on the fourth technological modernization of "Khimfarm" JSC, calculated for 2018-2022. It is planned to invest US dollars.

"In fact, the construction and modernization of all the main production facilities and additional logistics areas have been completed at the Khimfarm JSC plant in the city of Shymkent. Now the investment program will be focused on new projects in the field of automation and digitalization of production and additional processes, as well as projects in the field of quality control and management system.

Since 2009, a long-term contract system has been in operation in Kazakhstan with domestic manufacturers for the supply of pharmaceuticals for the needs of the healthcare system through a unique distributor. Only "Khimpharm" Ak itself currently has 5 signed contracts. According to them, we have the ability to carry out guaranteed delivery for medical institutions of the Republic of Kazakhstan. Long-term contracts allow investors to receive a contracted amount of sales. This encourages the creation of modern and competitive pharmaceutical industries. Investors can also receive preferences at the expense of investment contracts from the Ministry of Investments and Development, and domestic producers have the opportunity to receive loans at a discount from the Development Bank of Kazakhstan. Kazakhstan has developed various tools and mechanisms to support domestic producers and investors. "Khimpharm" JSC uses these tools as effectively as possible," said Rustam Baigarin, director of the "Khimpharm" JSC plant.

Today, more than 1,200 qualified employees work at the enterprise. Some of them have studied in foreign enterprises of the "Polpharma" group and in countries that are world leaders in the pharmaceutical industry (equipment manufacturers). The company registered 115 drugs belonging to 12 pharmacological groups. Thus, products of parenteral form (injections and infusions), solid form (tablets, capsules, sachet powder), aseptic powders of antibiotics, unsterilized solutions and syrups are produced. This is the fourth wave of modernization of Khimfarm JSC, the oldest pharmaceutical enterprise in the republic.  Elements of "Industry 4.0" are introduced in production. Thanks to additional reinvestments, new jobs will be created in the North Kazakhstan region," said Dauletkozha Mamyrov, regional director of JSC "KazakhInvest". It has 6 production plants, 6 research centers, more than 7300 employees. It is one of the 20 leading manufacturers of generic drugs in the world. The volume of sales is 1 billion per year. More than US dollars. The company's portfolio consists of more than 600 drugs, and there are more than 230 drugs in the development stage.

In the framework of the execution of the task of the head"KazakhInvest"in cooperation with the World Bank has developed the National Investment Strategy for 2018-2022. Work will be carried out in three directions: implementation of effective operational measures and development of new ways of attracting investments;  privatization and public-private partnership. The national strategy defines the priority industries for attracting foreign investments (industrial complex, machine building, chemistry and petrochemicals, infrastructure, mining and metallurgical complex, trade) and 11 priority countries (USA, Russian Federation, Great Britain, Germany, France, Italy, PRC, Japan, South Korea, Turkey, UAE) whose shares account for 80% of world investments. By 2022, the total flow of FDI will increase by 1.26 times; In 2022, the ratio of total FDI to GDP will increase to 19%; FDI aimed at increasing efficiency will increase by 1.5 times; the volume of investments in the fixed capital of the non-oil sector of the economy will increase by 1.46 times; it is planned that the amount of foreign investments in the fixed capital of the non-oil sector of the economy will increase by 1.5 times.

Source : https://www.gov.kz/memleket/entities/mps/press/news/details/25873?lang=kk